# EDGAR Filing Document

**Accession Number:** 0001738021
**File Stem:** 0001193125-23-009277
**Filing Date:** 2023-1
**Character Count:** 2412
**Document Hash:** fd4f74150a8f4226e2723b87768c24fe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-009277.hdr.sgml**: 20230217

**ACCESSION NUMBER**: 0001193125-23-009277

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230117

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Compass Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001738021
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135
- **BUSINESS PHONE:** 617-500-8099

**MAIL ADDRESS:**
- **STREET 1:** 80 GUEST STREET
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02135

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Olivia Ventures, Inc.
- **DATE OF NAME CHANGE:** 20180419

**COMPASS THERAPEUTICS, INC.** 

**80 Guest Street** 

**Suite 601** 

**Boston, Massachusetts 02135** 

January 17, 2023

**<u>Via EDGAR Transmission</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:

Re: <u>Withdrawal of Acceleration Request—Compass Therapeutics, Inc.: Registration Statement</u> <u>on</u>

<u>Form</u> <u>S-3 filed December</u> <u>2, 2022 (File No.</u> <u>333-268652)</u>

Ladies and Gentlemen:

Reference is made to our letter, filed as correspondence via EDGAR on January 13, 2023, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Tuesday, January 17, 2023, at 4:00 p.m. Eastern Time, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.

If you have any questions regarding this request for withdrawal, please contact James Xu of Goodwin Procter LLP at (650) 752-3355.

---

| |
|:---|
| Sincerely, |
| Compass Therapeutics, Inc. |
| /s/ Vered Bisker-Leib |
| Vered Bisker-Leib |
| President and Chief Operating Officer |

---

cc: Vered Bisker-Leib, *Compass Therapeutics, Inc.*

Jonathan Anderman, *Compass Therapeutics, Inc.*

Richard Hoffman, Esq., *Goodwin Procter LLP*

James Xu, Esq., *Goodwin Procter LLP*